Desloratadine relieves nasal congestion and improves quality‐of‐life in persistent allergic rhinitis
Authors:
Abstract
Background: Symptoms of allergic rhinitis (AR), particularly nasal congestion, can impair quality‐of‐life (QoL). However, only a modest correlation exists between these symptoms and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores, suggesting that both be evaluated for a complete assessment of health.Methods: Subjects with a ≥2‐year history of moderate‐to‐severe AR to dust mite or cat dander were randomized to desloratadine 5 mg/day (n = 293) or placebo/day (n = 291) for 28 days. Primary endpoint was change from baseline in a.m./p.m. nasal congestion score. Secondary outcomes included change from baseline in total nasal symptom score, individual symptom scores and RQLQ scores (completed on days 1, 7, and 28).Results: The Allergic Rhinitis and its Impact on Asthma criteria for persistent allergic rhinitis (PER) were fulfilled by 99% of subjects in the placebo arm. Between‐treatment difference in a.m./p.m. nasal congestion score, observed from day 8 onward, significantly favored desloratadine (P = 0.0003). Desloratadine significantly improved a.m./p.m. nasal congestion and RQLQ scores after 1 week and at treatment end (P < 0.05). Improvements in 5 of 7 RQLQ domain scores exceeded the minimal important difference. On days 7 and 28, desloratadine was also significantly superior to placebo in mean change from baseline in a.m./p.m. total nasal symptom score and rhinorrhea score (both P ≤ 0.01). Symptomatic benefit was primarily driven by improvement in nasal congestion and rhinorrhea.Conclusions: Desloratadine 5 mg/day significantly improved symptoms associated with PER, including nasal congestion, and provided significant improvement in QoL after 1 week of treatment.Keywords
This publication has 33 references indexed in Scilit:
- Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*Allergy, 2008
- Clinical Pharmacokinetics and Pharmacodynamics of Desloratadine, Fexofenadine and LevocetirizineClinical Pharmacokinetics, 2008
- A survey of the burden of allergic rhinitis in the USAAllergy, 2007
- Desloratadine therapy for symptoms associated with perennial allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2006
- Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trialAnnals of Allergy, Asthma & Immunology, 2006
- Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitisClinical & Experimental Allergy, 2004
- Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2002
- Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitisAnnals of Allergy, Asthma & Immunology, 1999
- Validating the SF-36 health survey questionnaire: new outcome measure for primary care.BMJ, 1992
- Measurement of health statusControlled Clinical Trials, 1989